BioNTech Buoyant On CAR-T/CARVac Combo Data
Promising Results Presented At AACR
CAR-T has revolutionized the treatment options for blood cancers but its application for solid tumors has fallen short. The German biotech hopes that by combining a CAR-T cell therapy with an mRNA vaccine could be a gamechanger.
You may also be interested in...
After many years of failures and setbacks, neoantigen-targeting immunotherapies are gaining momentum, with BioNTech and Roche among the frontrunners.
Its first COVID-19 vaccine failed last year, but fueled by payments from the EU, Germany and GSK, CureVac is trying again with two further versions of its mRNA platform.
The COVID-19 windfall meant a 12% rise in spending on medicines in the US in 2021 versus 2020, but just 5% excluding COVID, which is expected to fall to 1%-4% compound annual growth through 2026.